Global biopharmaceutical company AbbVie recently announced it had received U.S. Food and Drug Administration (FDA) approval for Humira® (adalimumab) as a treatment for non-infectious intermediate, posterior and panuveitis.
Humira reportedly targets and helps block TNF-α — a specific source of inflammation that can have a role in uveitis. The FDA approval is based on results from two Phase 3 studies, VISUAL-I and VISUAL-II, which demonstrated that adult patients with active and controlled non-infectious intermediate, posterior and panuveitis treated with HUMIRA had a significantly lower risk for treatment failure (a combination of uveitic flare and decrease in visual acuity), compared to placebo.
This FDA approval now reportedly makes Humira the first and only FDA-approved non-corticosteroid therapy available for adults with non-infectious intermediate, posterior and panuveitis. AbbVie also recently received approval from the European Commission for the use of Humira in the European Union for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
Click here to read the full press release.